- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04378023
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.
A prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radio-chemotherapy will be performed in this selected group.
The primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The secondary endpoints will be: 1) recurrence free survival at 1, 3 and 5 years post-transplant; 2) intention-to-treat survival of overall patients included in the study at 1,3 and 5 year; 3) the rate of patients included in the study who are finally transplanted.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A prospective multicentre pilot study which includes patients ≤ 70 years-old diagnosed of unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases.
The number of subjects necessary is 34 patients to achieve a power of 82% with a significance level of 0.05 to detect a 40% difference between the estimated 50% survival of those patients who are transplanted and 10% of those patients with hCCA unresectable who are not transplanted. This corresponds to a hazard ratio of 3.3219. Estimated loss to follow-up of 10% of patients.
RADIOLOGICAL EVALUATION
It will be considered unresectable those lesions Bismuth IV with the following criteria (Jarnagin WR, et al. Ann Surg 2001; 234:507; Memorial Sloan Kettering Cancer Center Hilar Cholangiocarcinoma Classification):
- Bilateral extension to second order biliary
- Unilateral extension to second-order biliary radicals AND contralateral portal vein involvement OR contralateral hepatic lobar atrophy
- Main or bilateral portal vein involvement
- Insufficient future liver remnant even after portal embolization
It will be performed the tumoral marker (CA 19.9), multiphase chest-abdomen CT scan, magnetic resonance cholangiopancreatography (MRCP) as well as positon emission tomography (PET)-scan if there is doubts of distant disease and upper endoscopic ultrasound (EUS) in order to rule out any obvious lymph node metastases. A biliary drainage will be placed by percutaneous transhepatic biliary drainage (PTBD) or endoscopic biliary drainage (EBD).
NEOADJUVANT TREATMENT
Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (1,330mg/m2).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv will be administered the day 1 and 8 every 21 days until transplant.
A staging laparotomy/laparoscopy is recommended before including the patient in waiting list for transplant to confirm the abscence of extra-hepatic disease, especially peritoneal seeding and lymph nodes involvement.
A score exception will be allowed to optimized the treatment received and to be transplanted during the first 6 months.
LIVER TRANSPLANT AND FOLLOW UP
Regarding liver transplant technique, hepatic artery should be avoided for arterial reconstruction using the splenic artery or an iliac conduit.
Biomarker analyses in the explant specimen will be performed.
The patient will be monitored post-operatively at the clinical, biological and morphological levels every 3 months during the first 2 years and every 6 months thereafter in order to detect any recurrence and in the context of standard clinical care.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: CRISTINA DOPAZO, MD/PhD
- Phone Number: +34932746113
- Email: cristina.dopazo@vallhebron.cat
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Department of HPB Surgery and Transplants, Hospital Vall d´Hebron
-
Contact:
- Cristina Dopazo, PhD/MD
- Phone Number: 6113 +34932746000
- Email: cristina.dopazo@vallhebron.cat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Those patients with unresectable malignant appearing hilar stricture and at least one of the following:
- Malignant cytology or histology
- CA 19.9>130U/mL without cholangits or/and jaundice
- Mass on cross-sectional imaging
Description
Inclusion Criteria:
- Willing and able to provide written consent form
- Age ≤ 70 years-old
- ECOG 0 or 1
- Unresectable hCCA ≤3cm in radial diameter
Exclusion Criteria:
- Those patients who have received chemotherapy or radiotherapy previously out of protocol
- Liver, extrahepatic or lymph node metastases
- Previous intent of surgical resection or percutaneous biopsy
- Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.
- Infection no controlled
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study group
Patients with unresectable hilar cholangiocarcinoma (hCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases
|
Patients will receive neoadjuvant radiotherapy (External - 50-54 grays) following by concomitant oral capecitabine (825mg/m2 bid).Thereafter, gemcitabine iv (1000mg/m2) plus cisplatin iv (25mg/m2) will be administered the day 1 and 8 every 21 days until transplant.
If no spread disease is discovered after neoadjuvant treatment, the patient will be listed for liver transplantation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival at 1, 3, and 5 years post-transplant
Time Frame: 5 years
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrence free survival at 1, 3 and 5 years post-transplant
Time Frame: 5 years
|
5 years
|
Intention-to-treat survival of overall patients included in the study at 1,3 and 5 year
Time Frame: 5 years
|
5 years
|
The rate of patients included in the study who are finally transplanted.
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cristina Dopazo, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
- Principal Investigator: Ramón Charco-Torra, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
- Study Chair: Sonia Pascual-Bartolomé, HOSPITAL GENERAL UNIVERSITARIO, ALICANTE
- Study Chair: Carmelo Loinaz-Segurola, Hospital Universitario 12 de Octubre, Madrid
- Study Chair: José María Álamo-Martinez, Hospital Universitario Virgen del Rocío, Sevilla
- Study Chair: José Luis Lucena de la Poza, Hospital Universitario Puerta de Hierro, Majadahonda
- Study Chair: Arturo Colon-Rodríguez, HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARANON, MADRID
- Study Chair: Diego López-Segarra, COMPLEJO HOSPITALARIO UNIVERSITARIO, BADAJOZ
- Study Chair: Yilliam Fundora-Suárez, Hospital Clinic of Barcelona
- Study Chair: Andrea Bosca-Robledo, Hospital Universitario La Fe
- Study Chair: Juan Andrés Echeverri-Cifuentes, Hospital Universitario Marqués de Valdecilla, Santander
- Study Chair: Josefina López-Domínguez, HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
- Study Chair: Xavier Merino-Casabiel, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
- Study Chair: David Leiva-Pedraza, HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
- Study Chair: María Teresa Salcedo-Allende, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA, BARCELONA
- Study Chair: José Antonio Gracia Solanas, HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA, ZARAGOZA
- Study Chair: Manuel Angel Barrera-Gómez, HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE LA CANDELARIA, TENERIFE
- Study Chair: Ricardo Robles-Campos, Hospital Universitario Virgen de la Arrixaca
- Study Director: Laura Lladó-Garrida, HOSPITAL UNIVERSITARIO DE BELLVITGE, BARCELONA
- Study Director: María Teresa Macarulla-Mercadé, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
- Study Director: Begoña Navalpotro-Yagüe, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
- Study Chair: Florian Castet, HOSPITAL UNIVERSITARIO VALL D´HEBRON, UNIVERSIDAD AUTONOMA DE BARCELONA
- Study Chair: Julio Santoyo, Hospital Regional Universitario de Malaga
- Study Chair: Manuel Durán Martínez, Hospital Universitario Reina Sofia de Cordoba
- Study Chair: Natalia Zambudio, Hospital Virgen de las Nieves (Granada)
Publications and helpful links
General Publications
- Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BS J, Youssef BA M, Klimstra D, Blumgart LH. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9. doi: 10.1097/00000658-200110000-00010.
- Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, Rosen CB. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004 May;24(2):201-7. doi: 10.1055/s-2004-828896.
- Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, Gores GJ, Nagorney DM. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61. doi: 10.1097/01.sla.0000179678.13285.fa.
- Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, Botha JF, Mezrich JD, Chapman WC, Schwartz JJ, Hong JC, Emond JC, Jeon H, Rosen CB, Gores GJ, Heimbach JK. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012 Jul;143(1):88-98.e3; quiz e14. doi: 10.1053/j.gastro.2012.04.008. Epub 2012 Apr 12.
- Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK. Transplantation Versus Resection for Hilar Cholangiocarcinoma: An Argument for Shifting Treatment Paradigms for Resectable Disease. Ann Surg. 2018 May;267(5):797-805. doi: 10.1097/SLA.0000000000002574.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- hCCA-LT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unresectable Cholangiocarcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma | Advanced CholangiocarcinomaUnited States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
Incyte CorporationRecruitingMetastatic Cholangiocarcinoma | Unresectable CholangiocarcinomaUnited States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
-
Hua LiRecruitingUnresectable Intrahepatic CholangiocarcinomaChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...AstraZeneca; Syndax PharmaceuticalsCompletedUnresectable Intrahepatic CholangiocarcinomaUnited States
-
Robert C. MartinUniversity of LouisvilleCompletedUnresectable Intrahepatic CholangiocarcinomaUnited States
-
Yale UniversityTerminatedUnresectable Intrahepatic CholangiocarcinomaUnited States
-
Zhongda HospitalCompleted
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
Clinical Trials on Neoadjuvant Chemo-radiotherapy
-
Harbin Medical UniversityUnknown
-
Beth Israel Medical CenterCompletedCancer of Head and NeckUnited States
-
The University of Hong KongRecruitingPredicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine LearningOral Squamous Cell CarcinomaHong Kong
-
Shanghai Chest HospitalRecruiting
-
University of ManchesterThe Christie NHS Foundation TrustUnknown
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 TreatmentChina
-
Sun Yat-sen UniversityWuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaboratorsRecruitingNasopharyngeal Cancer | Chemotherapy | Radiotherapy | PD-1 TherapyChina
-
Maastricht Radiation OncologyCompleted
-
Lawson Health Research InstituteRecruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Azienda Ospedaliero-Universitaria CareggiRecruitingEarly Breast CancerItaly